Authors




Siddhartha Yadav, MD, MBBS

Latest:

Input From a Multidisciplinary Team of Medical Providers is ‘Necessary’ to Manage Contralateral Breast Cancer, Says Expert

It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.


Scott A. Soefje, PharmD

Latest:

Non-BCMA Targeting Bispecifics in MM and Future Directions in Care

Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.


Terri Harrington, ANP-BC

Latest:

Biomarker Testing Best Practices for Informed Treatment Decision-Making: Med Onc and Nurse Perspectives

Panelists discuss the prevalence of PIK3CA mutations in HR positive (HR+)/ HER2 negative (HER2-) breast cancer, their prognostic implications, and the critical role of identifying these mutations for personalized treatment planning, while Ms. Harrington shares insights on common patient questions about biomarker testing, the importance of molecular testing, and educational resources for helping patients understand their test results; Dr Kaklamani addresses how the approval of inavolisib may prompt routine PIK3CA mutation testing in the frontline setting, and Dr Isaacs and Ms. Diaz discuss the infrastructure changes needed in community practices to support this shift and the lessons learned from evolving biomarker testing practices.


Ajai Chari, MD

Latest:

Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy in early relapsed multiple myeloma can provide deep and durable responses for eligible patients, though patient selection, timing of referral, manufacturing logistics, and management of adverse effects remain important considerations in optimizing outcomes.


Ulka N. Vaishampayan, MBBS

Latest:

Practice Pearls for Optimizing the Management of Advanced RCC

Experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.



Andrea C. Enzinger, MD

Latest:

Guidelines for Opioid Use in Cancer Management are Needed, Expert Says

Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.


Nausheen Ahmed, MD

Latest:

Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections

A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.


Patrick Travis, MD

Latest:

Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

The discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.


Patrick L. Wagner, MD, MPH

Latest:

Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis

Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.


Tejo N. Musunuru, MD

Latest:

Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple Myeloma

A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.


Rachel Heist, MD

Latest:

Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood Cancer

Rahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.


Deborah Abrams Kaplan

Latest:

Multiprong Leukemia Efforts Boost the Atlantic Health System Heme/Onc Program

An upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.



Jessica Frakes, MD

Latest:

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.


Gregory Gan, MD, PhD

Latest:

A Multidisciplinary Approach to Treating Resectable NSCLC

Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.


Zachary M. Avigan, MD

Latest:

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.



Annel Urena

Latest:

Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma

The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.



Sarah Donahue, MPH, NP

Latest:

Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.


Malaika Rehmani, MBBS

Latest:

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.


Thomas J. George, MD

Latest:

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.



Aparna Raj Parikh, MD, MS

Latest:

Treatment Decision-Making in Colon Cancer

Aparna Parikh, MD, and the Oncology Brothers have a comprehensive discussion on treatment decision-making practices for patients with colon cancer, highlighting considerations such as high microsatellite instability and refractory disease.



Jonathan R. Day, MD, PharmD

Latest:

Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is New

Jonathan R. Day, MD, PharmD, and Brian K. Link, MD, give their perspective on emerging treatments for follicular lymphoma.


Krina K. Patel, MD

Latest:

Looking Ahead and Key Takeaways

Panelists discuss how looking ahead, key takeaways from the CARTITUDE-4 study underscore the transformative potential of ciltacabtagene autoleucel in managing lenalidomide-refractory multiple myeloma, highlighting its efficacy, safety, and implications for future treatment strategies.